Skip to main content

Table 3 Efficacy of ART-123 vs placebo in France and ROW

From: Efficacy and safety of human soluble thrombomodulin (ART-123) for treatment of patients in France with sepsis-associated coagulopathy: post hoc analysis of SCARLET

Mortality rate, %

Subpopulation

ART-123

Placebo

ARR (95% CI)

FAS

Global

26.8

29.4

2.55 (− 3.68, 8.77)

France

17.3

25.7

8.3 (− 4.79, 21.47)

ROW

29.1

30.2

1.1 (− 5.87, 8.16)

Baseline coagulopathya

France

15.6

29.0

13.4 (− 0.97, 27.79)

ROW

29.6

32.8

3.2 (− 4.86, 11.26)

No baseline heparin

France

13.0

29.5

16.6 (0.4, 32.77)

ROW

29.7

31.8

2.0 (− 8.65, 12.74)

  1. ARR absolute risk reduction, CI confidence interval, FAS full analysis set, INR international normalized ratio, ROW rest of world
  2. aCoagulopathy was defined as INR > 1.4 without other known etiology and platelet count > 30 × 109/L at baseline